Journal of Tumor

ISSN-Online: 1819-6187; Frequency: Annual, Instant published;The first Issue: June, 2013; Full Open Access; Publishing fee

SCOPE: The journal publishes original research, reviews and other material related to breast cancer, gastrointestinal cancer, hematologic malignancies, molecular oncology, lung cancer, genitourinary cancer, head and neck cancer, pediatric oncology, neurooncology, supportive care and quality of life issues, prevention, and phase I and clinical pharmacology. The journal publishes research papers in areas of research include, but are not limited to, the following: Clinical diagnosis, laboratory diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional treatment, minimally invasive therapy, and robot-assisted therapy.

MISSION: The mission of the journal is the rapid exchange of scientific information between clinicians and scientists worldwide, seeks to publish high-quality practical and clinical research around new and existing therapies in all areas of cardiology. The mission of the journal is the rapid exchange of scientific information between clinicians and scientists worldwide.

Editor In Chief
Yoshihito Yokoyama, born on January 25, 1963. He has been Associate Professor at the Department of Obstetrics and Gynecology, Hirosaki University Graduate School of Medicine, Aomori, Japan.More
Cover Image
Figure 1 Crude mortality rates of C43 and C44 (from 1999 through 2014) by 5-year age groups. More
  • AIM: Prostate specific antigen (PSA) is a widely utilized screening marker for prostate cancer. Its performance in detecting prostate cancer is enhanced with the 5α-reductase inhibitor (5aRI) dutasteride. We evaluated if PSA density velocity (PSADV) further improved the ability to predict prostate cancer risk on repeat biopsy utilizing the REDUCE trial data in order to avoid unnecessary biopsies. MATERIALS AND METHODS: The REDUCE study randomized 8 231 men aged 50 to 75 years with a PSA between 2.5 and 10 ng/mL and a previously benign prostate biopsy. Prostate volume, PSA and biopsy results at 24 months were available for 1 074 subjects. PSADV, defined as the change in PSA density divided by the number of days between PSA measurements (ng/mL/cc/day), was calculated and compared between the placebo and treatment groups and further stratified by prostate biopsy results. Statistical significance was calculated using the Wilcoxon rank sum test.More

Vol 10, No 1 (2022)

Table of Contents

Original Article

Key Players and Potential Therapies in the Development of Breast Cancer Metastasis to the Spine PDF HTML
Zumana Khair, Effie Mouhtouris, Julia L. Gregory, Gerald Quan 590-601

ISSN: 1819-6187